Does Farxiga Cause Weight Loss?
Farxiga (dapagliflozin), an SGLT2 inhibitor for type 2 diabetes, heart failure, and chronic kidney disease, leads to modest weight loss in clinical trials, typically 2-4% of body weight over 6-12 months.[1][2] This averages 4-8 pounds for someone weighing 200 pounds, driven by the drug's mechanism of excreting glucose and calories through urine (about 200-300 calories daily).[3]
How Does Farxiga Promote Weight Loss?
It blocks sodium-glucose cotransporter 2 in the kidneys, increasing urinary glucose loss, which reduces calorie retention and shifts fluid balance.[1] Weight reduction is mostly fat mass, with some initial water loss; studies show sustained effects up to two years in diabetes patients.[2][4]
How Much Weight Loss to Expect?
In trials like DECLARE-TIMI 58 (17,000+ patients), Farxiga users lost 2.9 kg (6.4 lbs) on average at 4 years, versus 1.7 kg gain in placebo.[2] Non-diabetic heart failure patients saw 2-3 kg loss.[5] Results vary by dose (10 mg daily standard), diet, exercise, and baseline weight—obese patients lose more.
Who Sees the Best Results?
Type 2 diabetes patients with higher baseline BMI (>30) average 3-5% loss; men lose slightly more than women due to higher muscle mass and calorie excretion.[3][4] It's not FDA-approved for weight loss alone, unlike Wegovy or Zepbound, but off-label use occurs in obesity with comorbidities.
Weight Loss Compared to Other SGLT2 Inhibitors
Farxiga matches Jardiance (empagliflozin) at ~3 kg average loss, outperforming Invokana (canagliflozin) slightly in head-to-head data.[6] All exceed metformin (1-2 kg loss) but trail GLP-1 agonists like Ozempic (10-15% loss).[7]
| Drug | Avg. Weight Loss (1 year) | Primary Indication |
|------|---------------------------|-------------------|
| Farxiga | 3-4 kg | Diabetes/HF/CKD |
| Jardiance | 3-4 kg | Diabetes/HF/CKD |
| Ozempic | 8-12 kg | Diabetes/weight loss |
Does the Weight Loss Last Long-Term?
Yes, in extensions of trials like DAPA-HF, loss plateaus after 6-12 months but holds for 3+ years with continued use.[5] Stopping Farxiga often leads to regain within months, as calorie excretion halts.[4]
Side Effects Tied to Weight Loss
Common: urinary tract infections (9%), dehydration (from diuresis), genital infections (5-10%). Rare ketoacidosis or bone fractures; monitor hydration.[1] Weight loss slows if infections occur.
Can You Use Farxiga Just for Weight Loss?
Not recommended without diabetes, heart failure, or CKD—prescribed off-label sometimes, but guidelines prioritize approved uses. Consult a doctor; it's $500-600/month without insurance.[8]
Alternatives for Weight Loss
- GLP-1 drugs: Ozempic/Wegovy (10-20% loss), but nausea common.
- Other SGLT2s: Similar modest effects, cheaper generics emerging.
- Lifestyle: Diet/exercise matches Farxiga's loss without drugs.
[1]: Farxiga prescribing information, AstraZeneca (FDA label).
[2]: NEJM, DECLARE-TIMI 58 trial (2019).
[3]: Diabetes Care, SGLT2 mechanism review (2020).
[4]: Lancet, DAPA-CKD trial (2020).
[5]: NEJM, DAPA-HF trial (2019).
[6]: Head-to-head meta-analysis, Cardiovasc Diabetol (2021).
[7]: STEP trials, NEJM (2021).
[8]: GoodRx pricing data (2024).